Rezolute, Inc. (RZLT)
RZLT Stock Price Chart
Explore Rezolute, Inc. interactive price chart. Choose custom timeframes to analyze RZLT price movements and trends.
RZLT Company Profile
Discover essential business fundamentals and corporate details for Rezolute, Inc. (RZLT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
14 Jan 2013
Employees
74.00
Website
https://www.rezolutebio.comCEO
Nevan Charles Elam
Description
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
RZLT Financial Timeline
Browse a chronological timeline of Rezolute, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 16 Sept 2026
EPS estimate is -$0.13.
Earnings released on 12 May 2026
EPS came in at -$0.16 falling short of the estimated -$0.14 by -12.28%.
Earnings released on 12 Feb 2026
EPS came in at -$0.22 falling short of the estimated -$0.16 by -37.50%.
Earnings released on 6 Nov 2025
EPS came in at -$0.18 surpassing the estimated -$0.27 by +33.33%.
Earnings released on 17 Sept 2025
EPS came in at -$0.26 falling short of the estimated -$0.23 by -13.04%.
Earnings released on 13 May 2025
EPS came in at -$0.27 falling short of the estimated -$0.22 by -22.73%.
Earnings released on 12 Feb 2025
EPS came in at -$0.22 surpassing the estimated -$0.33 by +33.33%.
Earnings released on 7 Nov 2024
EPS came in at -$0.22 surpassing the estimated -$0.35 by +37.14%.
Earnings released on 19 Sept 2024
EPS came in at -$0.44 falling short of the estimated -$0.30 by -46.67%, while revenue for the quarter reached $58.00k .
Earnings released on 15 May 2024
EPS came in at -$0.34 matching the estimated -$0.34.
Earnings released on 13 Feb 2024
EPS came in at -$0.27 matching the estimated -$0.27.
Earnings released on 13 Nov 2023
EPS came in at -$0.28 surpassing the estimated -$0.33 by +15.15%.
Earnings released on 14 Sept 2023
EPS came in at -$0.25 surpassing the estimated -$0.34 by +26.47%.
Earnings released on 11 May 2023
EPS came in at -$0.30 surpassing the estimated -$0.31 by +3.23%.
Earnings released on 10 Feb 2023
EPS came in at -$0.26 surpassing the estimated -$0.33 by +21.21%.
Earnings released on 9 Nov 2022
EPS came in at -$0.19 surpassing the estimated -$0.31 by +38.71%.
Earnings released on 15 Sept 2022
EPS came in at -$0.37 falling short of the estimated -$0.34 by -8.82%.
Earnings released on 12 May 2022
EPS came in at -$0.65 surpassing the estimated -$0.86 by +24.42%.
Earnings released on 9 Feb 2022
EPS came in at -$0.80 falling short of the estimated -$0.77 by -3.90%.
Earnings released on 12 Nov 2021
EPS came in at -$0.92 falling short of the estimated -$0.90 by -2.22%.
Earnings released on 15 Sept 2021
EPS came in at -$0.78 surpassing the estimated -$0.82 by +4.88%.
RZLT Stock Performance
Access detailed RZLT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
